BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study of BMS-863233 in Patients With Hematologic Cancer
- Conditions
- Refractory Hematologic Cancer
- Interventions
- Drug: Cdc7-inhibitor (BMS-863233)
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT00838890
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Roswell Park, Buffalo, New York, United States
Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00836602
- Locations
- 🇦🇺
Local Institution, Heidelberg, Victoria, Australia
Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)HIV Infections
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 185
- Registration Number
- NCT00833482
- Locations
- 🇺🇸
West Coast Clinical Trials, Llc, Cypress, California, United States
🇳🇱Local Institution, Nijmegen, Netherlands
Phase III Acute Coronary Syndrome
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7484
- Registration Number
- NCT00831441
- Locations
- 🇺🇸
Central Jersey Medical Research Center, Elizabeth, New Jersey, United States
🇺🇸Delmarva Heart Research Foundation, Salisbury, Maryland, United States
🇺🇸Washington University School Of Medicine, St. Louis, Missouri, United States
Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT00828646
- Locations
- 🇯🇵
Local Institution, Yokohama, Kanagawa, Japan
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment
- Conditions
- Liver Cancer
- Interventions
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 587
- Registration Number
- NCT00825955
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸UF Health Clinical Research Center, Gainesville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 209
- Registration Number
- NCT00810147
- Locations
- 🇺🇸
Yale University School Of Medicine, New Haven, Connecticut, United States
🇺🇸Global Medical Institutes, Llc, Princeton, New Jersey, United States
🇺🇸University Of Rochester, Rochester, New York, United States
Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy
- Conditions
- Solid TumorBreast Cancer
- Interventions
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 29
- Registration Number
- NCT00803556
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00803374
- Locations
- 🇺🇸
Local Institution, New York, New York, United States
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 111
- Registration Number
- NCT00798252
- Locations
- 🇨🇦
Local Institution, Toronto, Ontario, Canada
🇺🇸Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States